Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dextromethorphan + guaifenesin + phenylephrine is a fixed-dose combination of three active ingredients used for the relief of symptoms associated with cold and respiratory infections. Dextromethorphan is an antitussive that suppresses the cough reflex by acting on the brain to decrease activity in the cough center[1][2]. Guaifenesin is an expectorant that helps loosen and thin mucus in the airways, making it easier to clear phlegm[3]. Phenylephrine is a decongestant that acts as a selective alpha-1 adrenergic receptor agonist, narrowing blood vessels in the nasal passages to reduce congestion[3]. This combination is indicated for temporary relief of cough due to minor throat and bronchial irritation, nasal congestion, and to help with mucus clearance[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextromethorphan + guaifenesin + phenylephrine.